Lisata Therapeutics (LSTA) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to -$4.2 million.
- Lisata Therapeutics' Income from Continuing Operations rose 1381.34% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.2 million, marking a year-over-year increase of 1204.44%. This contributed to the annual value of -$20.0 million for FY2024, which is 410.27% up from last year.
- According to the latest figures from Q3 2025, Lisata Therapeutics' Income from Continuing Operations is -$4.2 million, which was up 1381.34% from -$4.7 million recorded in Q2 2025.
- Lisata Therapeutics' Income from Continuing Operations' 5-year high stood at -$4.0 million during Q2 2023, with a 5-year trough of -$6.2 million in Q1 2023.
- Its 3-year average for Income from Continuing Operations is -$5.0 million, with a median of -$4.9 million in 2024.
- Examining YoY changes over the last 5 years, Lisata Therapeutics' Income from Continuing Operations showed a top increase of 1407.27% in 2024 and a maximum decrease of 2525.45% in 2024.
- Lisata Therapeutics' Income from Continuing Operations (Quarter) stood at -$5.4 million in 2023, then increased by 14.07% to -$4.6 million in 2024, then grew by 7.83% to -$4.2 million in 2025.
- Its last three reported values are -$4.2 million in Q3 2025, -$4.7 million for Q2 2025, and -$4.7 million during Q1 2025.